Abstract:Bipolar affective disorder is a common neuropsychiatric disorder. Although its neurobiological underpinnings are incompletely understood, the dopamine hypothesis has been a key theory of the pathophysiology of both manic and depressive phases of the illness for over four decades. The increased use of antidopaminergics in the treatment of this disorder and new in vivo neuroimaging and post-mortem studies makes it timely to review this theory. To do this, we conducted a systematic search for post-mortem, pharmacological, functional magnetic resonance and molecular imaging studies of dopamine function in bipolar disorder. Converging findings from pharmacological and imaging studies support the hypothesis that a state of hyperdopaminergia, specifically elevations in D2/3 receptor availability and a hyperactive reward processing network, underlies mania. In bipolar depression imaging studies show increased dopamine transporter levels, but changes in other aspects of dopaminergic function are inconsistent. Puzzlingly, pharmacological evidence shows that both dopamine agonists and antidopaminergics can improve bipolar depressive symptoms and perhaps actions at other receptors may reconcile these findings. Tentatively, this evidence suggests a model where an elevation in striatal D2/3 receptor availability would lead to increased dopaminergic neurotransmission and mania, whilst increased striatal dopamine transporter (DAT) levels would lead to reduced dopaminergic function and depression. Thus, it can be speculated that a failure of dopamine receptor and transporter homoeostasis might underlie the pathophysiology of this disorder. The limitations of this model include its reliance on pharmacological evidence, as these studies could potentially affect other monoamines, and the scarcity of imaging evidence on dopaminergic function. This model, if confirmed, has implications for developing new treatment strategies such as reducing the dopamine synthesis and/or release in mania and DAT blockade in bipolar depression.

Therapeutic approaches employing natural compounds and derivatives for treating bipolar disorder: emphasis on experimental models of the manic phase

Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder

Pushing the Frontiers: Optogenetics for Illuminating the Neural Pathophysiology of Bipolar Disorder

Inflammation in Bipolar Disorder (BD): Identification of new therapeutic targets

Involvement of Kynurenine Metabolism in Bipolar Disorder: an Updated Review

Promising avenues of therapeutics for bipolar illness

Drug Repurposing and Personalized Treatment Strategies for Bipolar Disorder Using Transcriptomic

Blood-brain barrier dysfunction in bipolar disorder: Molecular mechanisms and clinical implications

Neurobiology of Bipolar Disorder: Abnormalities on Cognitive and Cortical Functioning and Biomarker Levels.

Novel experimental and early investigational drugs for the treatment of bipolar disorder

Development progress of drugs for bipolar disorder: 75 Years after lithium proved effective

The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment

Role of Protein Kinase C in Bipolar Disorder: A Review of the Current Literature

Mood Stabilizers in Psychiatric Disorders and Mechanisms Learnt from In Vitro Model Systems

Metabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine

The bipolarity of light and dark: A review on Bipolar Disorder and circadian cycles

An update on adjunctive treatment options for bipolar disorder

Current issues in bipolar disorder: A critical review

Linking Mitochondrial Dysfunction, Neurotransmitter, and Neural Network Abnormalities and Mania: Elucidating Neurobiological Mechanisms of the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder

Mitochondrial Dysfunction in the Pathophysiology of Bipolar Disorder: Effects of Pharmacotherapy

Potential Therapeutic Effects of Physical Exercise for Bipolar Disorder